The purpose of this study is to evaluate the effect of repeated doses of the drug Lu AG06466 on the exposure of metoprolol, midazolam and bupropion
On Day 1, midazolam and metoprolol will be dosed as an oral single-dose cocktail and PK sampling will be performed for 48 hours. On Day 3, bupropion will be dosed as a single oral dose and PK sampling will be performed for 48 hours. On Days 5-18, subjects will be dosed with Lu AG06466 once daily. On Day 15, midazolam and metoprolol will be dosed as an oral single-dose cocktail and PK sampling will be performed for 48 hours. On Day 17, bupropion will be dosed as a single oral dose and PK sampling will be performed for 48 hours.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
15
10, 20, 30 mg/day oral capsules on Day 5-18
4 mg syrup, oral single dose on Day 1 and Day 15
100 mg tablets, oral single dose on Day 1 and Day 15
Covance Dallas CRU
Dallas, Texas, United States
AUC 0-inf for midazolam
Area under the midazolam plasma concentration-time curve from zero to infinity
Time frame: Day 1 and Day 15
AUC 0-inf for metoprolol
Area under the metoprolol plasma concentration-time curve from zero to infinity
Time frame: Day 1 and Day 15
AUC 0-inf for bupropion
Area under the bupropion plasma concentration-time curve from zero to infinity
Time frame: Day 3 and Day 17
Cmax for midazolam
Maximum observed plasma concentration for midazolam
Time frame: Day 1 and Day 15
Cmax for metoprolol
Maximum observed plasma concentration for metoprolol
Time frame: Day 1 and Day 15
Cmax for bupropion
Maximum observed plasma concentration for bupropion
Time frame: Day 3 and Day 17
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
100 mg tablets, oral single dose on Day 3 and Day 17